SC 13G

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Paratek Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

699374302

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

1 of 8

CUSIP No. 699374302   13G Page 2 of 11

1	NAME OF REPORTING PERSONS NexPoint Real Estate Opportunities, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a)  ☐ (b)  ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 50,000
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 50,000

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 50,000
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.01%
12	TYPE OF REPORTING PERSON* OO

CUSIP No. 699374302   13G Page 3 of 11

1	NAME OF REPORTING PERSONS Drugcrafters, LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a)  ☐ (b)  ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 303,367
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 303,367

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 303,367
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.6%
12	TYPE OF REPORTING PERSON PN

CUSIP No. 699374302   13G Page 4 of 11

1	NAME OF REPORTING PERSONS Highland Small-Cap Equity Fund
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a)  ☐ (b)  ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 64,770
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 64,770

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 64,770
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.13%
12	TYPE OF REPORTING PERSON IV

CUSIP No. 699374302   13G Page 5 of 11

1	NAME OF REPORTING PERSONS The Dugaboy Investment Trust
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a)  ☐ (b)  ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 2,474,060
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 2,474,060

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,474,060
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.93%
12	TYPE OF REPORTING PERSON OO

CUSIP No. 699374302   13G Page 6 of 11

1	NAME OF REPORTING PERSONS James D. Dondero
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a)  ☐ (b)  ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 2,892,197
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 2,892,197

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,892,197
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.7%
12	TYPE OF REPORTING PERSON HC, IN

CUSIP No. 699374302   13G Page 7 of 11

SCHEDULE 13G

This Schedule 13G (this “Filing”) is being filed on behalf of Drugcrafters, LP a Delaware limited partnership (“Drugcrafters”), The Dugaboy Investment Trust, a Delaware Trust (the “Trust”), Highland Small-Cap Equity Fund (“Highland”), a Massachusetts investment company, NexPoint Real Estate Opportunities, LLC (“NREO”), a Delaware limited liability company and James D. Dondero (collectively, the “Reporting Persons”).

Item 1(a) Name of Issuer.

Paratek Pharmaceuticals, Inc.

Item 1(b) Address of Issuer’s Principal Executive Offices.

75 Park Plaza

Boston, Massachusetts 02116

Item 2(a) Name of Person Filing.

(1) Drugcrafters, LP

(2) Highland Small-Cap Equity Fund

(3) NexPoint Real Estate Opportunities, LLC

(4) The Dugaboy Investment Trust

(5) James D. Dondero

Item 2(b) Address of Principal Business Office, or, if none, Residence.

For all Filers:

300 Crescent Court, Suite 700

Dallas, Texas 75201

Item 2(c) Citizenship or Place of Organization.

(1) Drugcrafters, LP is a Delaware limited partnership

(2) Highland Small-Cap Equity Fund is a Massachusetts investment company

(3) NexPoint Real Estate Opportunities, LLC is a Delaware limited liability company

(4) James D. Dondero is a United States citizen

(5) The Dugaboy Investment Trust is a Delaware trust

CUSIP No. 699374302   13G Page 8 of 11

Item 2(d) Title of Class of Securities.

Common Stock, par value $0.001 per share

Item 2(e) CUSIP Number.

699374302

Item 3 Reporting Person.

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

 (a)    ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 (b)    ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 (c)    ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 (d)    ☒ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

 (e)    ☐ An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E).

 (f)    ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

 (g)    ☒ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

 (h)    ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

 (i)    ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

 (j)    ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4 Ownership.

(a) Amount beneficially owned:

Drugcrafters, LP: 303,367

Highland Small-Cap Equity Fund: 64,770

NexPoint Real Estate Opportunities, LLC: 50,000

The Dugaboy Investment Trust: 2,474,060

James D. Dondero: 2,892,197

CUSIP No. 699374302   13G Page 9 of 11

(b) Percent of Class:

Drugcrafters, LP: 0.6%

Highland Small-Cap Equity Fund: 0.13%

NexPoint Real Estate Opportunities, LLC: 0.1%

The Dugaboy Investment Trust: 4.93%

James D. Dondero: 5.7%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Drugcrafters, LP: 0

Highland Small-Cap Equity Fund: 0

NexPoint Real Estate Opportunities, LLC: 0

NexPoint Advisors, L.P.: 0

The Dugaboy Investment Trust: 0

James D. Dondero: 0

(ii) Shared power to vote or direct the vote:

Drugcrafters, LP: 303,367

Highland Small-Cap Equity Fund: 64,770

NexPoint Real Estate Opportunities, LLC: 50,000

The Dugaboy Investment Trust: 2,474,060

James D. Dondero: 2,892,197

(iii) Sole power to dispose or to direct the disposition of:

Drugcrafters, LP: 0

Highland Small-Cap Equity Fund: 0

NexPoint Real Estate Opportunities, LLC: 0

NexPoint Advisors, L.P.: 0

The Dugaboy Investment Trust: 0

James D. Dondero: 0

CUSIP No. 699374302   13G Page 10 of 11

(iv) Shared power to dispose or to direct the disposition of:

Drugcrafters, LP: 303,367

Highland Small-Cap Equity Fund: 64,770

NexPoint Real Estate Opportunities, LLC: 50,000

The Dugaboy Investment Trust: 2,474,060

James D. Dondero: 2,892,197

Item 5 Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ]

Item 6 Ownership of More Than Five Percent on Behalf of Another Person.

Inapplicable.

Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.

Inapplicable.

Item 8 Identification and Classification of Members of the Group.

Inapplicable.

Item 9 Notice of Dissolution of Group.

Inapplicable.

Item 10 Certification.

By signing below each of the Reporting Persons certifies that, to the best of such person’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 699374302   13G Page 11 of 11

Exhibits Exhibit 99.1

Joint Filing Agreement, dated March 10, 2022, by and among Drugcrafters, Highland, NREO, the Trust and James Dondero.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 11, 2022

DRUGCRAFTERS, LP
	By:	/s/ James D. Dondero
		Name:  James D. Dondero
		Title:  Managing Member of the General Partner
HIGHLAND SMALL-CAP EQUITY FUND
	By:	/s/ Frank Waterhouse
		Name:  Frank Waterhouse
		Title:  Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer and Treasurer
NexPoint Real Estate Opportunities, LLC
	By:	/s/  Brian Mitts
		Name:  Brian Mitts
		Title:  Authorized Signatory
THE DUGABOY INVESTMENT TRUST
	By:	/s/ Nancy Dondero
		Name:  Nancy Dondero
		Title:  Trustee

/s/ James D. Dondero

James D. Dondero

EX-99.1

EXHIBIT 99-1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.001 per share, of Paratek Pharmaceuticals, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13G and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.

This Joint Filing Agreement may be signed in counterparts with the same effect as if the signature on each counterpart were upon the same instrument.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of March 11, 2022.

DRUGCRAFTERS, LP
	By:	/s/ James D. Dondero
		Name:  James D. Dondero
		Title:  Managing Member of the General Partner
HIGHLAND SMALL-CAP EQUITY FUND
	By:	/s/ Frank Waterhouse
		Name:  Frank Waterhouse
		Title:  Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer and Treasurer
NexPoint Real Estate Opportunities, LLC
	By:	/s/  Brian Mitts
		Name:  Brian Mitts
		Title: Authorized Signatory

THE DUGABOY INVESTMENT TRUST
By:	/s/ Nancy Dondero
Name:  Nancy Dondero
Title:  Trustee
/s/ James D. Dondero
James D. Dondero